


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound represented by the formula (I):



wherein R^7 and R^{21} [[,]] are the same or are different [[,]] and represent

- 1) a C_2 to C_{22} alkoxy group which may have a substituent,
- 2) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- 3) a C_7 to C_{22} aralkyloxy group which may have a substituent,
- 4) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,
- 5) $RC(=Y)-O-$, wherein Y represents an oxygen atom or sulfur atom, and R represents
 - a) a hydrogen atom,
 - b) a C_2 to C_{22} alkyl group which may have a substituent,
 - c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,
 - d) a C_6 to C_{14} aryl group which may have a substituent, or
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - f) a C_7 to C_{22} aralkyl group which may have a substituent,
 - g) a 5-membered to 14-membered heteroaralkyl group which may have a

~~substituent,~~

~~h) a C₁ to C₂₂ alkoxy group which may have a substituent,~~

~~i) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,~~

~~j) a C₆ to C₁₄ aryloxy group which may have a substituent, or~~

~~k) a C₃ to C₁₄ cycloalkyl group which may have a substituent,~~

~~l) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or~~

~~m) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,~~

6) $R^{S1}R^{S2}R^{S3}SiO-$, wherein R^{S1} , R^{S2} and R^{S3} , the same or different, represent

a) a C₁ to C₆ alkyl group or

b) a C₆ to C₁₄ aryl group,

7) a halogen atom,

[[8)]] $R^{N1}R^{N2}N-R^M-$, wherein R^M represents

a) a single bond,

b) -CO-O-,

e) -SO₂-O-,

[[d)]] c) -CS-O- or

[[e)]] d) -CO-NR^{N3}-, wherein R^{N3} represents a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent, provided that, the leftmost bond in b) to e) is bonded to the nitrogen atom, and

wherein R^{N1} and R^{N2} [[,]] are the same or are different [[,]] and represent

- a) a hydrogen atom,
- b) a C₁ to C₂₂ alkyl group which may have a substituent,
- c) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
- d) an aliphatic C₂ to C₂₂ acyl group which may have a substituent,
- e) an aromatic C₇ to C₁₅ acyl group which may have a substituent,
- f) a C₆ to C₁₄ aryl group which may have a substituent,
- g) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- h) a C₇ to C₂₂ aralkyl group which may have a substituent,
- i) a C₁ to C₂₂ alkylsulfonyl group which may have a substituent,
- j) a C₆ to C₁₄ arylsulfonyl group which may have a substituent,
- k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{N1} and R^{N2} together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,
- l) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- m) a C₃ to C₁₄ cycloalkyl group which may have a substituent or
- n) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent [[,]]

9) ~~R^{N4}SO₂O~~, wherein ~~R^{N4}~~ represents

- ~~a) a C₁ to C₂₂ alkyl group which may have a substituent,~~
- ~~b) a C₆ to C₁₄ aryl group which may have a substituent,~~
- ~~c) a C₁ to C₂₂ alkoxy group which may have a substituent,~~

- ~~d) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,~~
- ~~e) a C₆ to C₁₄ aryloxy group which may have a substituent,~~
- ~~f) a 5-membered to 14 membered heteroaryloxy group which may have a substituent,~~
- ~~g) a C₇ to C₂₂ aralkyloxy group which may have a substituent or~~
- ~~h) a 5 membered to 14 membered heteroaralkyloxy group which may have a substituent,~~

10) (R^{N5}O)₂PO-O-, wherein R^{N5} represents

- ~~a) a C₁ to C₂₂ alkyl group which may have a substituent,~~
- ~~b) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,~~
- ~~c) a C₆ to C₁₄ aryl group which may have a substituent,~~
- ~~d) a 5 membered to 14 membered heteroaryl group which may have a substituent,~~
- ~~e) a C₇ to C₂₂ aralkyl group which may have a substituent or~~
- ~~f) a 5 membered to 14 membered heteroaralkyl group which may have a substituent,~~

11) (R^{N1}R^{N2}N)₂PO-O-, wherein R^{N1} and R^{N2} are the same as defined above or

12) (R^{N1}R^{N2}N)(R^{N5}O)PO-O-, wherein R^{N1}, R^{N2} and R^{N5} are the same as defined above; or


a pharmacologically acceptable salt thereof,

wherein said substituents are each independently selected from the group consisting of:

C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group,

piperadyl group, piperidyl group and pyrridyl group.

2. (Currently Amended) The compound according to claim 1 represented by the formula (I-a):



wherein R^{7a} and R^{21a} [[,]] are the same or are different [[,]] and represent

- 1) ~~a C₂ to C₂₂ alkoxy group which may have a substituent,~~
- 2) ~~an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,~~
- 3) ~~a C₇ to C₂₂ aralkyloxy group which may have a substituent,~~
- 4) ~~R^aC(=Y^a)-O-, wherein Y^a represents an oxygen atom or sulfur atom, and R^a represents~~
 - a) ~~a hydrogen atom,~~
 - b) ~~a C₂ to C₂₂ alkyl group which may have a substituent,~~
 - c) ~~an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,~~
 - d) ~~a C₆ to C₁₄ aryl group which may have a substituent, or~~
 - e) ~~a 5-membered to 14-membered heteroaryl group which may have a substituent,~~
 - f) ~~a C₇ to C₂₂ aralkyl group which may have a substituent,~~
 - g) ~~a 5-membered to 14-membered heteroaralkyl group which may have a~~

~~substituent,~~

~~h) a C₁ to C₂₂ alkoxy group which may have a substituent,~~

~~i) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,~~

~~j) a C₆ to C₁₄ aryloxy group which may have a substituent, or~~

~~k) a 3-membered to 14-membered heteroaryloxy group which may have a substituent,~~

[[5]] R^{aN1}R^{aN2}N-CO-O-, wherein R^{aN1} and R^{aN2}, the same or different, represent

a) a hydrogen atom,

b) a C₁ to C₂₂ alkyl group which may have a substituent,

c) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,

d) a C₆ to C₁₄ aryl group which may have a substituent,

e) a 5-membered to 14-membered heteroaryl group which may have a substituent,

f) a C₇ to C₂₂ aralkyl group which may have a substituent,

g) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN1} and R^{aN2} together in combination with the nitrogen atom to which R^{aN1} and R^{aN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

h) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

i) a C₃ to C₁₄ cycloalkyl group which may have a substituent or

j) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, or

6) $R^{aN1}R^{aN2}N-SO_2-O-$, wherein R^{aN1} and R^{aN2} are the same as defined above,

[[7)] $R^{aN1}R^{aN2}N-CS-O-$, wherein R^{aN1} and R^{aN2} are the same as defined above,

8) $RaN4SO_2-O-$, wherein $RaN4$ represents

- a) a C1 to C22 alkyl group which may have a substituent,
- b) a C6 to C14 aryl group which may have a substituent,
- c) a C1 to C22 alkoxy group which may have a substituent,
- d) an unsaturated C2 to C22 alkoxy group which may have a substituent,
- e) a C6 to C14 aryloxy group which may have a substituent,
- f) a 5 membered to 14 membered heteroaryloxy group which may have a substituent,
- g) a C7 to C22 aralkyloxy group which may have a substituent or
- h) a 5 membered to 14 membered heteroaralkyloxy group which may have a substituent,

9) $(R^{aN5}O)_2PO-O-$, wherein R^{aN5} represents

- a) a C₁ to C₂₂ alkyl group which may have a substituent,
- b) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
- c) a C₆ to C₁₄ aryl group which may have a substituent,
- d) a 5 membered to 14 membered heteroaryl group which may have a substituent,
- e) a C₇ to C₂₂ aralkyl group which may have a substituent or
- f) a 5 membered to 14 membered heteroaralkyl group which may have a substituent,

10) $(R^{aN1}R^{aN2}N)_2PO-O-$, wherein R^{aN1} and R^{aN2} are the same as defined above or

11) $(R^{aN1}R^{aN2}N)(R^{aN3}O)POO$, wherein R^{aN1} , R^{aN2} and R^{aN3} are the same as defined

above; or a pharmacologically acceptable salt thereof,

wherein said substituents are each independently selected from the group consisting of:

C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.

3. (Currently Amended) The compound according to claim 1, wherein R^7 and/or R^{21} represent a ~~C₇ to C₂₂ aralkyloxy group which may have a substituent~~, $RC(=Y)-O-$, wherein Y and R are the same as defined above, or $R^{N1}R^{N2}N-R^M$, wherein R^M represents

a) $-CO-O-$ or


b) $-CS-O-$, ~~and R^{N1} and R^{N2} are the same as defined above~~, provided that, the leftmost bond in a) and b) is bonded to the nitrogen atom; or a pharmacologically acceptable salt thereof,

wherein said substituents are each independently selected from the group consisting of:

C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.


4. (Currently Amended) The compound according to claim 1, wherein R^{N1} and R^{N2} ~~[[,]]~~ are the same or are different ~~[[,]]~~ and represent a C₁ to C₆ alkyl group or C₆ to C₁₄ aryl group, or

form, together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, a non-aromatic heterocyclic group selected from the group consisting of:



or a pharmacologically acceptable salt thereof.

5. (Currently Amended) The compound according to claim 2 represented by the formula (I-b):




wherein R^{7b} and R^{21b} ~~[[,]]~~ are the same or are different ~~[[,]]~~ and represent ~~a C_7 to C_{22} aralkyloxy group which may have a substituent, or $R^b-C(=Y^b)-O-$, wherein Y^b represents an oxygen atom or sulfur atom, and R^b , the same or different, represents~~

a) a hydrogen atom,

b) a C_2 to C_6 alkyl group ~~which may have a substituent,~~

- [[c)]] a C₆ to C₁₄ aryl group which may have a substituent, or
- ~~d) a 5-membered to 14-membered heteroaryl group which may have a substituent,~~
- ~~e) a C₇ to C₁₀ aralkyl group which may have a substituent,~~
- ~~f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,~~
- ~~g) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,~~
- h) a group of the formula (III):



wherein A) n represents an integer of 0 to 4,

X_b represents

- i) -CHR^{bN4}-,
- ii) -NR^{bN5}-,
- iii) -O-,
- iv) -S-,
- v) -SO- or
- vi) -SO₂-,

R^{bN1} represents

- i) a hydrogen atom or
- ii) a C₁ to C₆ alkyl group which may have a substituent,

R^{bN2} represents

- i) a hydrogen atom or
- ii) a C_1 to C_6 alkyl group which may have a substituent,

R^{bN3} and R^{bN4} , the same or different, represent

- i) a hydrogen atom,
- ii) a C_1 to C_6 alkyl group which may have a substituent,
- iii) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- iv) a C_6 to C_{14} aryl group which may have a substituent,
- v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- vi) a C_7 to C_{10} aralkyl group which may have a substituent,
- vii) a C_3 to C_8 cycloalkyl group which may have a substituent,
- viii) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- xi) $-NR^{bN6}R^{bN7}$, wherein R^{bN6} and R^{bN7} , the same or different, represent a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent or
- xii) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN3} and R^{bN4} together in combination with the carbon atom to which R^{bN3} and R^{bN4} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and

R^{bN5} represents

- i) a hydrogen atom,
- ii) a C₁ to C₆ alkyl group which may have a substituent,
- iii) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- iv) a C₆ to C₁₄ aryl group which may have a substituent,
- v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- vi) a C₇ to C₁₀ aralkyl group which may have a substituent,
- vii) a C₃ to C₈ cycloalkyl group which may have a substituent,
- viii) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or
- xi) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN3} and R^{bN5} together in combination with the nitrogen atom to which R^{bN3} and R^{bN5} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

B)

X_b, n, R^{bN3}, R^{bN4} and R^{bN5} represent the same group as defined above, and R^{bN1} and R^{bN2} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN1} and R^{bN2} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

C)


X_b, n, R^{bN2}, R^{bN4} and R^{bN5} represent the same group as defined above, and R^{bN1} and R^{bN3}

represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN1} and R^{bN3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

D)

X_b , n, R^{bN1} , R^{bN4} and R^{bN5} represent the same group as defined above, and R^{bN2} and R^{bN3} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN2} and R^{bN3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

i) a group of the formula (IV):



wherein R^{bN8} and R^{bN9} , the same or different, represent

- i) a hydrogen atom,
 - ii) a C_1 to C_6 alkyl group which may have a substituent,
 - iii) a C_6 to C_{14} aryl group which may have a substituent,
 - iv) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - v) a C_7 to C_{10} aralkyl group which may have a substituent or
 - vi) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; or
- a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of:

C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.

6. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{al}C(=Y^{al})-O-, wherein Y^{al} represents an oxygen atom ~~or sulfur atom~~, and R^{al} represents

[[1]]) a hydrogen atom, or

~~2) a C₂ to C₆ alkyl group which may have a substituent,~~

~~3) a C₆ to C₁₀ aryl group which may have a substituent,~~


~~4) a 5-membered to 14-membered heteroaryl group which may have a substituent,~~

~~5) a C₇ to C₁₀ aralkyl group which may have a substituent or~~

~~6) a 5-membered to 14-membered heteroaralkyl group which may have a substituent;~~ or a pharmacologically acceptable salt thereof,

wherein said substituents are each independently selected from the group consisting of:
C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.

7. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a2}C(=Y^{a2})-O-$, wherein Y^{a2} represents an oxygen atom ~~or sulfur atom~~, and R^{a2} represents a group of the formula (III'):



wherein A) n represents an integer of 0 to 4,

X_1 represents

- 1) $-CHR^{aN9}-$,
- 2) $-NR^{aN10}-$,
- 3) $-O-$,
- 4) $-S-$,
- 5) $-SO-$ or
- 6) $-SO_2-$,

R^{aN6} and R^{aN7} , the same or different, represent

- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent,

R^{aN8} and R^{aN9} , the same or different, represent


- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

- 4) a C₆ to C₁₄ aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- 11) -NR^{aN11}R^{aN12}, wherein R^{aN11} and R^{aN12}, the same or different, represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or
- 12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN8} and R^{aN9} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and R^{aN10} represents
 - 1) a hydrogen atom,
 - 2) a C₁ to C₆ alkyl group which may have a substituent,
 - 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
 - 4) a C₆ to C₁₄ aryl group which may have a substituent,
 - 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
 - 7) a C₃ to C₈ cycloalkyl group which may have a substituent,

- 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- 11) a 5-membered to 14-membered non-aromatic heterocyclic group formed by the nitrogen atom to which R^{aN10} is bonded, and one substituent selected from the group consisting of R^{aN6}, R^{aN7} and R^{aN8} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or
- 12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by the nitrogen atom to which R^{aN10} is bonded, and two substituents selected from the group consisting of R^{aN6}, R^{aN7} and R^{aN8} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or
- B) n, X₁, R^{aN7}, R^{aN9} and R^{aN10} represent the same group as defined above, and R^{aN6} and R^{aN8} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN6} and R^{aN8} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent; or a pharmacologically acceptable salt thereof.

8. (Previously Presented) The compound according to claim 7, wherein X₁ represents -NR^{aN10}-, wherein NR^{aN10} is the same as defined above; or a pharmacologically acceptable salt thereof.

9. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a3}C(=Y^{a3})-O-$, wherein Y^{a3} represents an oxygen atom ~~or sulfur atom~~, and R^{a3} represents a group of the formula (V):



wherein n represents an integer of 0 to 4,

R^{aN13} represents

- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent, and

R^{aN14} represents

- 1) a hydrogen atom,
- 2) an amino group which may have a substituent,
- 3) a pyridinyl group which may have a substituent,
- 4) a pyrrolidin-1-yl group which may have a substituent,
- 5) a piperidin-1-yl group which may have a substituent,
- 6) a morpholin-4-yl group which may have a substituent or
- 7) a piperazin-1-yl group which may have a substituent; or a pharmacologically


acceptable salt thereof,

wherein said substituents are each independently selected from the group consisting of:

C_1 - C_6 alkyl group, phenyl group, halogen, hydroxyl group, C_1 - C_6 alkoxy group, thiol group, C_1 -

C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxy carbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.

10. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a4}CO-O-, wherein R^{a4} represents a group of the formula (VI):



wherein n₁ and n₂ [[,]] are the same or are different [[,]] and represent an integer of 0 to 4,

X₂ represents

- 1) -CHR^{aN17}-,
- 2) -NR^{aN18}-,
- 3) -O-,
- 4) -S-,
- 5) -SO- or
- 6) -SO₂-,

R^{aN15} represents

- 1) a hydrogen atom or
- 2) a C₁ to C₆ alkyl group which may have a substituent,

R^{aN16} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) a C₆ to C₁₄ aryl group which may have a substituent or
- 4) a C₇ to C₁₀ aralkyl group which may have a substituent,

R^{aN17} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- 4) a C₆ to C₁₄ aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 10) -NR^{aN19}R^{aN20}, wherein R^{aN19} and R^{aN20}, the same or different, represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or
- 11) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and


R^{aN18} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,

- 4) a C₆ to C₁₄ aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of: C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.

11. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a5}CO-O-, wherein R^{a5} represents a group of the formula (VII):



wherein n₃ represents 1 or 2,

R^{aN21} represents


- 1) a hydrogen atom or
- 2) a C₁ to C₆ alkyl group which may have a substituent, and

R^{aN22} represents

- 1) a hydrogen atom or
- 2) a C₁ to C₆ alkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of: C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.

12. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a6}CO-O-, wherein R^{a6} represents a group of the formula (VIII):



wherein n₁ and n₂ [[,]] are the same or are different [[,]] and represent an integer of 0 to 4,

X₃ represents

- 1) -CHR^{aN25}-,

2) $\text{-NR}^{\text{aN26}}\text{-}$,

3) -O- ,

4) -S- ,

5) -SO- or

6) $\text{-SO}_2\text{-}$,

R^{aN23} represents

1) a hydrogen atom or

2) a C_1 to C_6 alkyl group which may have a substituent,

R^{aN24} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) a C_6 to C_{14} aryl group which may have a substituent or

4) a C_7 to C_{10} aralkyl group which may have a substituent,

R^{aN25} represents

1) a hydrogen atom,

2) a C_1 to C_6 alkyl group which may have a substituent,

3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

4) a C_1 to C_6 alkoxy group which may have a substituent,

5) a C_6 to C_{14} aryl group which may have a substituent,

6) a 5-membered to 14-membered heteroaryl group which may have a substituent,

7) a C_7 to C_{10} aralkyl group which may have a substituent,

8) a C_3 to C_8 cycloalkyl group which may have a substituent,

- 9) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 10) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 11) -NR^{aN27}R^{aN28}, wherein R^{aN27} and R^{aN28}, the same or different, represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or
- 12) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and

R^{aN26} represents


- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- 4) a C₆ to C₁₄ aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or

a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of: C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino

group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.

13. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a7}CO-O-, wherein R^{a7} represents a group of the formula (IX):



wherein n₄ represents an integer of 1 to 3, and


R^{aN29} represents

- 1) an amino group which may have a substituent,
- 2) a pyrrolidin-1-yl group which may have a substituent,
- 3) a piperidin-1-yl group which may have a substituent or
- 4) a morpholin-4-yl group which may have a substituent; or

a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of: C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.

14. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a8}CO-O-$, wherein R^{a8} represents a group of the formula (X):



wherein n_4 represents an integer of 1 to 3,

R^{aN30} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_6 to C_{14} aryl group which may have a substituent or
- 4) a C_7 to C_{10} aralkyl group which may have a substituent, and


R^{aN31} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 4) a 3-membered to 8-membered non-aromatic heterocyclic group which may have a substituent,
- 5) a C_6 to C_{14} aryl group which may have a substituent,
- 6) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 7) a C_7 to C_{10} aralkyl group which may have a substituent,
- 8) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

9) a C₄ to C₉ cycloalkylalkyl group which may have a substituent; or
a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of:
C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-
C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino
group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group,
piperadyl group, piperidyl group and pyrridyl group.

15. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a}
represent R^{a9}CO-O-, wherein R^{a9} represents a group of the formula (XI):



wherein n₄ represents an integer of 1 to 3, and


R^{aN32} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 4) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 5) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 6) a pyridyl group which may have a substituent or

7) a tetrahydropyranyl group which may have a substituent; or
a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of:
C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-
C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino
group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group,
piperadyl group, piperidyl group and pyrridyl group.

16. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a10}CO-O-, wherein R^{a10} represents a group of the formula (XII):



wherein m₁, m₂, m₃ and m₄, the same or differently, represent 0 or 1,

n₄ represents an integer of 1 to 3, and

R^{aN33} represents


- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- 4) a C₆ to C₁₄ aryl group which may have a substituent,

- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or

a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of: C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.


17. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a11}CO-O-, wherein R^{a11} represents a group of the formula (XIII):




wherein m₅ represents an integer of 1 to 3, and n₅ represents 2 or 3; or a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of: C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

18. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a12}CO-O-, wherein R^{a12} represents a group selected from a group consisting of:



or a group selected from a group consisting of



and both of which may have a substituent on the ring;

or a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of: C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxycarbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyrridyl group.

19. (Previously Presented) The compound according to claim 1, which is (8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricos-8,12,14-trien-11-olide, (8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-21-N,N-dimethylcarbamoyloxy-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricos-8,12,14-trien-11-olide and (8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-21-phenylcarbamoyloxy-18,19-epoxytricos-8,12,14-trien-11-olide; or a pharmacologically acceptable salt thereof.

20. (Cancelled)

21. (Previously Presented) A pharmaceutical composition comprising the compound according to claim 1, or a pharmacologically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier.

22-45. (Cancelled)